✦ LIBER ✦

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

✍ Scribed by Takahashi, Naoto; Miura, Masatomo; Scott, Stuart A; Kagaya, Hideaki; Kameoka, Yoshihiro; Tagawa, Hiroyuki; Saitoh, Hirobumi; Fujishima, Naohito; Yoshioka, Tomoko; Hirokawa, Makoto

Book ID: 115491192
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 333 KB
Volume: 55
Category: Article
ISSN: 1435-232X
DOI: 10.1038/jhg.2010.98

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Influence of enzyme and transporter poly

Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients

✍ Seong, S. J.; Lim, M.; Sohn, S. K.; Moon, J. H.; Oh, S.- J.; Kim, B. S.; Ryoo, H 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 85 KB

Trough plasma concentration of imatinib

Trough plasma concentration of imatinib reflects BCR–ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: A report from the BINGO study

✍ Yuichi Ishikawa; Hitoshi Kiyoi; Keisuke Watanabe; Koichi Miyamura; Yasuyuki Naka 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 374 KB

Association of genotypes and haplotypes

Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients

✍ Au, Anthony; Aziz Baba, Abdul; Goh, Ai Sim; Wahid Fadilah, S. Abdul; Teh, Alan; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 763 KB

Deletions of the Derivative Chromosome 9

Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis

✍ Castagnetti, F.; Testoni, N.; Luatti, S.; Marzocchi, G.; Mancini, M.; Kerim, S.; 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 138 KB

Multicenter phase II clinical trial of n

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib

✍ Takahashi, Naoto; Miura, Masatomo; Kuroki, Jun; Mitani, Kinuko; Kitabayashi, Ats 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 344 KB